Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Meridian Bioscience is an integrated life science company. The Company is engaged in developing, manufacturing, selling, and distributing clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics, and Life Science.

CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET.

Meridian Bioscience to Participate in Canaccord Genuity Virtual MedTech & Diagnostics Forum

Meridian Bioscience's (VIVO) CEO Jack Kenny on Q4 2020 Results - Earnings Call Transcript

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 35.71% and 7.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Q4 Earnings and Revenues Top Estimates

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2020 financial results Friday, November 13, 2020.

Meridian Bioscience to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on November 13, 2020

Clearfield

Camping World Hlds

eGain

Green Brick Partners

Goosehead Insurance

Superior Uniform Group

Despite the huge market rally since March, there are still some great value buys among small-cap stocks, if you know where to look. The post 7 Overlooked Small-Cap Stocks To Buy For Growth appeared first on InvestorPlace.

7 Overlooked Small-Cap Stocks To Buy For Growth

CINCINNATI, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a complete solution improving the development of cancer diagnostic tests, allowing direct RNA and DNA detection from liquid biopsy samples such as whole blood.

Meridian Bioscience Launches a Complete Solution to Support Liquid Biopsy Cancer Diagnostics

CINCINNATI, Sept.  14, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science critical raw materials, is pleased to announce the launch of a novel highly sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to accelerate development of COVID-19 assays from patient saliva. Coronavirus-neutralizing antibodies primarily target the trimeric spike (S) glycoprotein on the viral surface that mediates entry into the host cell. This antibody pair binds to recombinant SARS-CoV-2 trimeric spike protein.

Meridian launches a novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva samples

CINCINNATI, Aug.  31, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will present at the H. C. Wainright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 12:30pm ET.

Meridian Bioscience to Present at the H. C. Wainright 22nd Annual Global Investment Conference

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q3 2020 Results - Earnings Call Transcript

Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 129.17% and 28.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Meridian Bioscience (VIVO) Beats Q3 Earnings and Revenue Estimates

CINCINNATI, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fiscal third quarter ended June 30, 2020.

Meridian Bioscience Reports Fiscal Third Quarter 2020 Operating Results – Best Quarter in Company History – Raises Full Year Guidance

Meridian Bioscience's (VIVO) fiscal third-quarter results are likely to reflect strong performance by Life Science business line.

What's in Store for Meridian Bioscience's (VIVO) Q3 Earnings?

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Meridian Bioscience (VIVO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

CINCINNATI, July  28, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announces the appointment of Anthony Bihl III to its Board of Directors, effective immediately.

Meridian Bioscience Announces New Board Member - Anthony Bihl

CINCINNATI, July  16, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report third quarter 2020 financial results Friday, August 7, 2020.

Meridian Bioscience to Hold Third Quarter 2020 Financial Results Conference Call on August 7, 2020

CINCINNATI, July  13, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that it has launched a high-sensitivity SARS-CoV-2 nucleocapsid antibody pair for the development of rapid COVID-19 antigen assays.

Meridian Bioscience Announces the Launch of a High-Sensitivity SARS-CoV-2 Nucleocapsid Antibody Pair for the Development of Rapid COVID-19 Antigen Assays

Fortinet

NextEra Energy

Keeping the coronavirus impact in mind, we have shortlisted five stocks that can return well on investment in the second half of 2020.

5 Stocks to Wade Through Hurdles in Second-Half 2020

eXp World Holdings Inc

iClick Interactive Asia Group

Kiniksa Pharmaceuticals Ltd

Lakeland Industries

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks With Recent Price Strength Amid Spike in Coronavirus

Meridian Bioscience has thrived during the COVID-19 pandemic. Can this stock go much higher, or is it time to cash out?

Is It Time to Cash In on Meridian Bioscience?

Axcelis Technologies

FormFactor

Logitech

Teekay Tankers

Zoom Video

Zynex Inc

This selection of growth stocks includes some surprise choices and companies set to benefit from the lasting effects of the pandemic.

7 A-Rated Growth Stocks That Are Loaded With Long-Term Potential

Meridian Bioscience (VIVO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Meridian Bioscience (VIVO) Soars to 52-Week High, Time to Cash Out?

CINCINNATI, May  26, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of diagnostic testing solutions and life science raw materials, announced today that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA), with projected production schedules of tens of millions of COVID-19 antibody tests per month.

Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month

CINCINNATI, May  20, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc.’s (NASDAQ: VIVO) Board of Directors announced that Tony Serafini-Lamanna has been promoted to Executive Vice President of Diagnostics.  Jack Kenny remains Chief Executive Officer of Meridian, while passing responsibility of the Diagnostics division to Mr. Serafini-Lamanna, who becomes an officer of the company.  This change was effective May 18, 2020. 

Meridian Bioscience Promotes Tony Serafini-Lamanna to Executive Vice President of Diagnostics

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2020 Results-Earnings Call Transcript

CINCINNATI, May  08, 2020  (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2020.

News for Meridian Bioscience Stock (VIVO)